Leidos Holdings, Inc. - LDOS STOCK NEWS

Leidos (NYSE:LDOS) has formed a strategic partnership with the University of Edinburgh to advance AI and data science solutions through the university's Bayes Centre. The collaboration aims to address challenges in environmental, civil, healthcare, and national security sectors by combining Leidos' Trusted Mission AI solutions with the university's research expertise. The partnership will provide access to a talent pool of over 45,000 students through internships and joint projects. The Bayes Centre, a £45M innovation hub, houses around 500 academics, students, and industry partners working on AI and data science initiatives.

Leidos (NYSE:LDOS) has secured a contract to modernize the Organ Procurement and Transplant Network (OPTN). The $235 million contract, awarded by the U.S. Department of Health and Human Services, includes a one-year base period with four one-year options. The project aims to improve the system that delivers organ transplant information to patients, donors, and healthcare providers.

As part of this multiple-award contract, Leidos will compete with other vendors to modernize key aspects of the organ transplant system, focusing on enhancing transparency, performance, governance, and efficiency. The initiative will benefit over 100,000 people on the national organ transplant waitlist and represents the most significant OPTN reforms in nearly 40 years.

Leidos has released its 15th annual sustainability report for 2023, highlighting the company's progress in environmental, social, and governance initiatives. The report, aligned with Global Reporting Initiative Standards, focuses on three key areas: cultivating inclusion, advancing environmental sustainability, and promoting healthier lives.

Key achievements include continuous reduction of scope 1 and 2 emissions since 2010, hiring over 2,200 veterans and military spouses, and maintaining strong community engagement through volunteerism and philanthropy. CEO Tom Bell emphasized that sustainability principles are integrated throughout Leidos's operations, programs, and decision-making processes.

Leidos (NYSE:LDOS) has secured a new contract to modernize the Organ Procurement and Transplant Network (OPTN), awarded by the U.S. Department of Health and Human Services. The multiple-award contract has a potential value of $235 million, including a one-year base period and four one-year options.

The company will compete with other vendors to modernize key aspects of the organ transplant system, aiming to improve transparency, performance, governance, and efficiency. This initiative will benefit over 100,000 people on the national organ transplant waitlist and represents the most significant OPTN reforms in nearly 40 years.

Leidos (NYSE:LDOS) has secured a new $93 million Technical Assistance for Repairables Processing (TARP) contract from the Naval Supply Systems Command Fleet Logistics Center. The contract includes a one-year base period with four one-year options and a six-month option. Under this contract, Leidos will develop a business intelligence dashboard and provide global field representatives to train U.S. Navy personnel on Reverse Supply Chain operations, including proper packaging of military assets and use of the electronic Retrograde Management System. This marks Leidos' seventh TARP program contract since 2000.

Leidos (LDOS) reported strong Q3 2024 results with revenues of $4.2 billion, up 7% year-over-year. Net income reached $362 million ($2.68 per diluted share), with a record adjusted EBITDA margin of 14.2%. The company achieved substantial net bookings of $8.1 billion with a book-to-bill ratio of 1.9. Based on strong performance, Leidos raised its FY2024 guidance, projecting revenues of $16.35-16.45 billion and non-GAAP diluted EPS of $9.80-$10.00. The company demonstrated robust cash flow generation with $656 million from operations and returned $254 million to shareholders through dividends and share repurchases.

Leidos Holdings (NYSE:LDOS) has announced a 5.3% increase in its quarterly cash dividend to $0.40 per share, up from the previous $0.38. The dividend will be paid on December 31, 2024, to stockholders of record as of December 16, 2024. Leidos, a Fortune 500® innovation company focused on national security and health solutions, employs 48,000 people globally and reported annual revenues of approximately $15.4 billion for the fiscal year ended December 29, 2023.

Leidos (NYSE:LDOS) has received a success memorandum from the Defense Innovation Unit (DIU) for completing key milestones in its Electric Vehicle Charging as a Service (EV CaaS) prototype for the Department of Air Force. The company becomes the sole vendor authorized to provide a FedRAMP-accredited budget-neutral EV CaaS solution for the Department of Defense and U.S. government. Leidos completed initial prototype milestones in under a year at three Air Force bases and was awarded its first production agreement for Edwards Air Force Base. The solution includes make-ready infrastructure, cybersecure EV charging facilities, and a budget-neutral business model.

Leidos (NYSE:LDOS) has been awarded a $331 million contract to modernize the U.S. Army's network, aligning with the Army's Network Modernization Strategy and Unified Network Plan. The contract, awarded by the Army Program Executive Office for Command, Control and Communications-Tactical Global Enterprise Network Modernization-OCONUS, has a one-year base period with four one-year options.

Leidos will deploy the Army's Global Unified Network (AGUN), which utilizes Software Defined Network technologies and supports the transition to a Zero Trust Architecture. This initiative aims to deliver a standardized, orchestrated modern network architecture, enhancing interoperability and security across all operational levels.

The project will make applications, data, and enterprise services accessible, trusted, and interoperable globally, supporting the Army's divestiture of Joint Regional Security Stacks.